【9 March, Hong Kong】 Recently, Fochon Pharmaceuticals., Ltd., (“Fochon Pharma”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock codes: 600196.SH, 02196.HK) received application acceptance notification (acceptance nos. CXHL2000046 (Guo) and CXHL2000047 (Guo)) for clinical trial registration from the National Medical Products Administration (NMPA) for its FCN-207 tablet, a new drug for the treatment of hyperuricemia or gout

FCN-207 tablet is an innovative small molecule chemical drug developed by Fosun Pharma and intended for the treatment of hyperuricemia or gout. As of January 2020, Fosun Pharma’s accumulated R&D input in FCN-207 tablets totalled approximately RMB 20.3 million (unaudited) for the current stage. 

So far, medicines with the same targets as FCN-207 tablets are available around the globe; however, there is still no such drug with independent intellectual property rights on the mainland Chinese market.